$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000112534518000097 Filed on November 07, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$15.79M	$20.80M	$1.663M
YoY Change	-89.63%	1150.63%	-48.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.50M	$9.600M	$8.400M
YoY Change	25.0%	14.29%	16.67%
% of Gross Profit
Research & Development	$46.90M	$46.22M	$40.98M
YoY Change	20.26%	12.77%	35.28%
% of Gross Profit
Depreciation & Amortization	$3.010M	$2.730M	$1.910M
YoY Change	124.63%	42.93%	-7.73%
% of Gross Profit
Operating Expenses	$57.50M	$46.22M	$40.98M
YoY Change	21.31%	12.77%	35.28%
Operating Profit		-$35.00M	-$47.72M
YoY Change		-26.65%	39.28%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$3.000M	$975.0K	$681.0K
YoY Change	-475.0%	43.17%	62.53%
Pretax Income	-$44.60M	-$34.00M	-$47.00M
YoY Change	-142.19%	-27.66%	39.05%
Income Tax
% Of Pretax Income
Net Earnings	-$44.64M	-$34.03M	-$47.04M
YoY Change	-142.23%	-27.66%	38.99%
Net Earnings / Revenue	-282.66%	-163.62%	-2828.8%
Basic Earnings Per Share			-$1.28
Diluted Earnings Per Share	-$1.054M	-$805.7K	-$1.28
COMMON SHARES
Basic Shares Outstanding	42.26M shares	42.24M shares	36.78M shares
Diluted Shares Outstanding			36.78M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$232.9M	$260.1M	$203.6M
YoY Change	-23.66%	27.75%	-34.55%
Cash & Equivalents	$220.1M	$201.8M	$90.88M
Short-Term Investments	$12.70M	$58.30M	$112.8M
Other Short-Term Assets	$6.700M	$4.500M	$3.700M
YoY Change	86.11%	21.62%	76.19%
Inventory
Prepaid Expenses	$6.678M	$4.315M	$3.261M
Receivables	$29.58M	$20.97M	$2.194M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$269.1M	$285.6M	$209.5M
YoY Change	-16.5%	36.37%	-33.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.71M	$58.65M	$30.84M
YoY Change	13.46%	90.18%	66.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$6.294M	$11.07M	$1.541M
YoY Change	292.88%	618.04%	-26.62%
Total Long-Term Assets	$63.01M	$69.71M	$32.38M
YoY Change	22.14%	115.31%	37.2%
TOTAL ASSETS
Total Short-Term Assets	$269.1M	$285.6M	$209.5M
Total Long-Term Assets	$63.01M	$69.71M	$32.38M
Total Assets	$332.1M	$355.4M	$241.8M
YoY Change	-11.17%	46.94%	-28.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.005M	$986.0K	$1.680M
YoY Change	63.4%	-41.31%	20.0%
Accrued Expenses	$33.20M	$38.48M	$25.50M
YoY Change	-13.96%	50.88%	65.59%
Deferred Revenue	$21.72M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$700.0K
YoY Change		-100.0%	-53.33%
Total Short-Term Liabilities	$59.94M	$48.03M	$32.44M
YoY Change	20.47%	48.05%	46.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$29.30M	$24.70M	$19.90M
YoY Change	17.67%	24.12%	17.06%
Total Long-Term Liabilities	$29.30M	$24.70M	$19.90M
YoY Change	17.67%	24.12%	12.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.94M	$48.03M	$32.44M
Total Long-Term Liabilities	$29.30M	$24.70M	$19.90M
Total Liabilities	$89.25M	$72.71M	$52.38M
YoY Change	19.57%	38.82%	31.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$490.3M	-$445.6M	-$418.1M
YoY Change	56.97%	6.59%
Common Stock	$733.2M	$728.3M	$607.6M
YoY Change	19.87%	19.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$242.9M	$282.6M	$189.5M
YoY Change
Total Liabilities & Shareholders Equity	$332.1M	$355.4M	$241.8M
YoY Change	-11.17%	46.94%	-28.85%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$44.64M	-$34.03M	-$47.04M
YoY Change	-142.23%	-27.66%	38.99%
Depreciation, Depletion And Amortization	$3.010M	$2.730M	$1.910M
YoY Change	124.63%	42.93%	-7.73%
Cash From Operating Activities	-$27.22M	-$36.98M	-$31.35M
YoY Change	-124.34%	17.96%	-162.96%
INVESTING ACTIVITIES
Capital Expenditures	-$710.0K	-$4.220M	-$9.850M
YoY Change	-93.4%	-57.16%	397.47%
Acquisitions
YoY Change
Other Investing Activities	$45.79M	$4.210M	$14.31M
YoY Change	136.03%	-70.58%	-1312.71%
Cash From Investing Activities	$45.07M	-$10.00K	$4.470M
YoY Change	421.64%	-100.22%	-241.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	470.0K	140.0K	1.150M
YoY Change	30.56%	-87.83%	13.86%
NET CHANGE
Cash From Operating Activities	-27.22M	-36.98M	-31.35M
Cash From Investing Activities	45.07M	-10.00K	4.470M
Cash From Financing Activities	470.0K	140.0K	1.150M
Net Change In Cash	18.32M	-36.85M	-25.73M
YoY Change	-84.84%	43.22%	-154.01%
FREE CASH FLOW
Cash From Operating Activities	-$27.22M	-$36.98M	-$31.35M
Capital Expenditures	-$710.0K	-$4.220M	-$9.850M
Free Cash Flow	-$26.51M	-$32.76M	-$21.50M
YoY Change	-121.62%	52.37%	-141.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42248075	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36859077	shares
	dei	Document Type DocumentType	10-Q
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42259080	shares
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201807000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211727000	USD
CY2018Q3	us-gaap	Investments Investments	58336000	USD
CY2017Q4	us-gaap	Investments Investments	93394000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20970000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13643000	USD
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4315000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3151000	USD
CY2018Q3	us-gaap	Other Assets OtherAssets	214000	USD
CY2017Q4	us-gaap	Other Assets OtherAssets	383000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	285642000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	322298000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58649000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49983000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11065000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1602000	USD
CY2018Q3	us-gaap	Assets Assets	355356000	USD
CY2017Q4	us-gaap	Assets Assets	373883000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	986000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2451000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	38477000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	38581000	USD
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7377000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7202000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1010000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1048000	USD
CY2018Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	298000	USD
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	175000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	175000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	48025000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49755000	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14134000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13637000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10553000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	11253000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	72712000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	74645000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	422000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	369000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	727849000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	611270000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-445627000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-312340000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-61000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	282644000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	299238000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	355356000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	373883000	USD
CY2018Q3	us-gaap	Revenues Revenues	20798000	USD
CY2017Q3	us-gaap	Revenues Revenues	1663000	USD
	us-gaap	Revenues Revenues	44327000	USD
	us-gaap	Revenues Revenues	5383000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46218000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40984000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	143902000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108246000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9584000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8403000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29953000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24249000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	55802000	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	49387000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	173855000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	132495000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35004000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-47724000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-129528000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-127112000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	975000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	681000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2719000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1759000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-34029000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-47043000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-126809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-125353000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-18000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	56000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	61000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	55000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-34047000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-46987000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126748000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-125298000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.28
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.50
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42239327	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36779305	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40462658	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35847449	shares
	us-gaap	Net Income Loss NetIncomeLoss	-126809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-125353000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5268000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5886000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12168000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11064000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7328000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-570000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1164000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-222000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9293000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-168000	USD
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1465000	USD
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2138000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9460000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9501000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-298000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-1176000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5807000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2666000	USD
	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-738000	USD
	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	6482000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-126006000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-97440000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	120039000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	89124000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	155848000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	177006000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24239000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18645000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11570000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	69237000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103259000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	34294000	USD
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	1257000	USD
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	695000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	104516000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	34989000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9920000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6786000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211727000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84098000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201807000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90884000	USD
	mgnx	Fair Value Of Warrants Received FairValueOfWarrantsReceived	6130000	USD
	mgnx	Fair Value Of Warrants Received FairValueOfWarrantsReceived	0	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7742000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	19576000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-318819000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-34029000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-126809000	USD
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7377000	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14134000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-445627000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27318000	USD
	mgnx	Contract With Customer Liability Increasefrom Cash Receipts ContractWithCustomerLiabilityIncreasefromCashReceipts	500000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6307000	USD
CY2018Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	21511000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6300000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58336000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	58336000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	93455000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	63000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	93394000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	4573000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	4001000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12168000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11064000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4504642	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.79
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1230244	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.43
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	205902	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	180709	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	24.25
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5348275	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19762000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3365982	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	18892000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5138801	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.79
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	19671000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.07
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4000000.0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	900000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11900000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	28000000.0	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M24D
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5348275	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5348275	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4533794	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4533794	shares

Files In Submission

Name	View Source	Status
0001125345-18-000097-index-headers.html	Edgar Link	pending
0001125345-18-000097-index.html	Edgar Link	pending
0001125345-18-000097.txt	Edgar Link	pending
0001125345-18-000097-xbrl.zip	Edgar Link	pending
exhibit31-1q32018.htm	Edgar Link	pending
exhibit31-2q32018.htm	Edgar Link	pending
exhibit32-1q32018.htm	Edgar Link	pending
exhibit32-2q32018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20180930.htm	Edgar Link	pending
mgnx-20180930.xsd	Edgar Link	pending
mgnx-20180930_cal.xml	Edgar Link	unprocessable
mgnx-20180930_def.xml	Edgar Link	unprocessable
mgnx-20180930_htm.xml	Edgar Link	completed
mgnx-20180930_lab.xml	Edgar Link	unprocessable
mgnx-20180930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2018 Q4 Form 10-Q Financial Statement

#000112534518000097 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2018 Q4 Form 10-Q Financial Statement

#000112534518000097 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx